You are here:

boceprevir (Victrelis) Experienced Patients

Advice

following a full submission

boceprevir (Victrelis®) is accepted for use within NHS Scotland.
 
Indication under review: Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who have failed previous therapy.

In the pivotal phase III randomised study, addition of boceprevir to current standard therapy in patients with HCV, who had failed previous therapy, increased the proportion of patients who achieved a sustained virologic response.
 

Drug Details

Drug Name: boceprevir (Victrelis) Experienced Patients
SMC Drug ID: 722/11
Manufacturer: Merck Sharp and Dohme Ltd
Indication: Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who have failed previous therapy.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 10 October 2011

Back